Samjin Pharm
Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases. It also… Read more
Samjin Pharm (005500) - Total Liabilities
Latest total liabilities as of September 2025: ₩184.63 Billion KRW
Based on the latest financial reports, Samjin Pharm (005500) has total liabilities worth ₩184.63 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Samjin Pharm - Total Liabilities Trend (2013–2024)
This chart illustrates how Samjin Pharm's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Samjin Pharm Competitors by Total Liabilities
The table below lists competitors of Samjin Pharm ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Imarketkorea
KO:122900
|
Korea | ₩891.72 Billion |
|
Polytronics Technology Corp
TW:6224
|
Taiwan | NT$1.79 Billion |
|
BTCS Inc
NASDAQ:BTCS
|
USA | $73.45 Million |
|
TOM Group Limited
PINK:TOCOF
|
USA | $4.47 Billion |
|
TerrAscend Corp.
OTCQX:TSNDF
|
USA | $459.78 Million |
|
Consumer Portfolio Services Inc
NASDAQ:CPSS
|
USA | $3.50 Billion |
|
Pricer AB (publ)
PINK:PCRBF
|
USA | $1.02 Billion |
|
Molecular Partners AG
PINK:MLLCF
|
USA | $16.62 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Samjin Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.70 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Samjin Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Samjin Pharm (2013–2024)
The table below shows the annual total liabilities of Samjin Pharm from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩163.51 Billion | +5.81% |
| 2023-12-31 | ₩154.54 Billion | +18.24% |
| 2022-12-31 | ₩130.69 Billion | +32.92% |
| 2021-12-31 | ₩98.33 Billion | +76.92% |
| 2020-12-31 | ₩55.58 Billion | +19.07% |
| 2019-12-31 | ₩46.68 Billion | +3.84% |
| 2018-12-31 | ₩44.95 Billion | -7.09% |
| 2017-12-31 | ₩48.38 Billion | -16.41% |
| 2016-12-31 | ₩57.88 Billion | -20.36% |
| 2015-12-31 | ₩72.67 Billion | -12.72% |
| 2014-12-31 | ₩83.26 Billion | -8.46% |
| 2013-12-31 | ₩90.96 Billion | -- |